Felix Seyfried

Ulm, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Therapeutic potential of BH3-mimetics and NK cell-mediated immunotherapy in T-ALL.

Therapeutic potential of BH3-mimetics and NK cell-mediated immunotherapy in T-ALL.

Journal: Cell death & disease

Published: May 15, 2025

Remission induction in refractory, drug resistant pediatric PICALM::MLLT10+ B-cell acute lymphoblastic leukemia by venetoclax.

Remission induction in refractory, drug resistant pediatric PICALM::MLLT10+ B-cell acute lymphoblastic leukemia by venetoclax.

Journal: Leukemia

Published: December 02, 2024

Editorial: Reviews in hematologic malignancies: 2023.

Editorial: Reviews in hematologic malignancies: 2023.

Journal: Frontiers in oncology

Published: April 05, 2024

The dual BCL-2 and BCL-XL inhibitor AZD4320 acts on-target and synergizes with MCL-1 inhibition in B-cell precursor ALL.

The dual BCL-2 and BCL-XL inhibitor AZD4320 acts on-target and synergizes with MCL-1 inhibition in B-cell precursor ALL.

Journal: Blood advances

Published: March 19, 2024

Venetoclax resistance in acute lymphoblastic leukemia is characterized by increased mitochondrial activity and can be overcome by co-targeting oxidative phosphorylation.

Venetoclax resistance in acute lymphoblastic leukemia is characterized by increased mitochondrial activity and can be overcome by co-targeting oxidative phosphorylation.

Journal: Cell death & disease

Published: November 17, 2023

Synergistic activity of combined inhibition of anti-apoptotic molecules in B-cell precursor ALL.

Synergistic activity of combined inhibition of anti-apoptotic molecules in B-cell precursor ALL.

Journal: Leukemia

Published: April 15, 2021

MCL-1 Inhibition Overcomes Anti-apoptotic Adaptation to Targeted Therapies in B-Cell Precursor Acute Lymphoblastic Leukemia.

MCL-1 Inhibition Overcomes Anti-apoptotic Adaptation to Targeted Therapies in B-Cell Precursor Acute Lymphoblastic Leukemia.

Journal: Frontiers in cell and developmental biology

Published: April 14, 2021

Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia.

Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia.

Journal: Blood

Published: March 01, 2021

Inhibiting casein kinase 2 sensitizes acute lymphoblastic leukemia cells to venetoclax via MCL1 degradation.

Inhibiting casein kinase 2 sensitizes acute lymphoblastic leukemia cells to venetoclax via MCL1 degradation.

Journal: Blood advances

Published: February 12, 2021

MicroRNA-497/195 is tumor suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia.

MicroRNA-497/195 is tumor suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia.

Journal: Blood

Published: June 10, 2020

Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling.

Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling.

Journal: Cell death & disease

Published: March 26, 2019

IL7R is associated with CNS infiltration and relapse in pediatric B-cell precursor acute lymphoblastic leukemia.

IL7R is associated with CNS infiltration and relapse in pediatric B-cell precursor acute lymphoblastic leukemia.

Journal: Blood

Published: August 30, 2018

Showing 1-12 of 18

Last Updated: 09/26/2026